Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business

Teleflex finalizes acquisition of Biotronik

Teleflex, a medical technology company, announced that it has finalized its acquisition of the vascular intervention business of Biotronik.In February, Teleflex entered into a definitive agreement with Biotronik to acquire its vascular intervention business for $895 million (€760 million).  Teleflex’s offerings include vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Biotro…

Teleflex completes acquisition of Biotronik’s Vascular Intervention business - Cardiovascular News

Teleflex today announced that is has completed the previously announced acquisition of substantially all of the Vascular Intervention business of Biotronik. The company notes in a press release that the acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products. On 27 February 2025, Teleflex announced its entry into a definitive agreement to acquire substantially all of Biotronik’s Vascul…

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the recent completion of its acquisition of substantially all of BIOTRONIK SE & Co. KG’s Vascular Intervention business. The €760 million deal, finalized earlier than anticipated, significantly expands Teleflex’s portfolio of interventional access products and strengthens its global reach in the growing peripheral intervention market. “We are pleased to announce the completion of the ac…